Schrödinger (NASDAQ:SDGR) Issues Earnings Results

Schrödinger (NASDAQ:SDGR - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20), Zacks reports. The firm had revenue of $88.32 million during the quarter, compared to the consensus estimate of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Schrödinger updated its FY 2025 guidance to EPS.

Schrödinger Price Performance

NASDAQ SDGR traded up $0.06 during trading on Friday, reaching $22.31. 1,071,695 shares of the company's stock traded hands, compared to its average volume of 1,027,856. Schrödinger has a 12-month low of $16.67 and a 12-month high of $29.15. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -9.53 and a beta of 1.61. The company's 50 day simple moving average is $22.34 and its two-hundred day simple moving average is $20.61.

Wall Street Analyst Weigh In

SDGR has been the subject of several analyst reports. Piper Sandler decreased their price objective on shares of Schrödinger from $50.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday. KeyCorp raised their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Finally, BMO Capital Markets raised their price objective on shares of Schrödinger from $25.00 to $28.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.29.

Remove Ads

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.